Evidence map›Paper›PMID 41028051›Full record

ArticleScientific reports2025

Design, synthesis, and antimicrobial evaluation of novel quinazoline piperazine phosphorodiamidate hybrids as potent DNA gyrase inhibitors.

Suresh Babu Donka, Sajitha Kethineni, Bala Yesu Valaparla, Anusha Bheemreddy, Manjunadh D Meti, Uttam A More, Venkata Subbaiah Kotakadi, Murali Vatturu, Srinivasulu Doddaga

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Design, Synthesis, and Biological Evaluation ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Suresh Babu DonkaDepartment of Chemistry, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India.
Sajitha KethineniDepartment of Chemistry, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India.
Bala Yesu ValaparlaDepartment of Chemistry, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India.
Anusha BheemreddyDepartment of Chemistry, Silver Jubilee Government College, Cluster University, Kurnool, 518502, Andhra Pradesh, India.
Manjunadh D MetiDepartment of Plant Sciences, School of Life Sciences, University of Hyderabad, Gachibowli, 500046, Telangana, India.
Uttam A MoreDepartment of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Suram, 394110, India.
Venkata Subbaiah KotakadiDST PURSE centre, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India.
Murali VatturuDepartment of Chemistry, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India.
Srinivasulu DoddagaDepartment of Chemistry, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India. doddaga_s@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance poses a critical challenge to global public health, exacerbating morbidity and mortality associated with bacterial infections. This study addresses the urgent need for novel antibacterial agents by exploring the design and synthesis of quinazoline-piperazine phosphorodiamidate hybrids (6a-g) as potential DNA gyrase inhibitors. Antibacterial activity was evaluated using the agar well diffusion method, revealing significant inhibition zones for compounds 6f, 6 g, 6a, and 6c compared to the standard drug Amoxyclav. Minimum inhibitory concentration (MIC) measurements further supported the potent antibacterial effects of these compounds. Additionally, compounds 6f, 6 g, and 6a exhibited notable antifungal activity superior to Fluconazole. Molecular docking simulations against DNA gyrase demonstrated strong binding affinities of compounds 6f and 6a with dock scores surpassing that of a standard antibiotic, ciprofloxacin. Detailed analysis of binding interactions highlighted key residues involved in stabilizing the ligand-protein complexes, providing insights into their mechanism of action. Furthermore, in silico ADMET prediction studies revealed that the targeted analogs satisfied the drug like characteristics of CNS acting drugs against antimicrobial diseases.

Indexed as

Anti-Bacterial AgentsDNA GyrasePiperazinesQuinazolinesTopoisomerase II InhibitorsDrug DesignMicrobial Sensitivity TestsMolecular Docking SimulationPiperazineAnti-Bacterial AgentsDNA GyrasePiperazinePiperazinesQuinazolinesTopoisomerase II InhibitorsAnti-microbial activityIn Silico studiesMorpholinePhosphorodiamidatePiperazineQuinazoline

Identifiers

PMID41028051
PMCPMC12484721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.